Form 4: ClearPoint Neuro CFO's RSU Vesting and Tax Sale

ClearPoint Neuro's CFO, Danilo D'Alessandro, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Summary

• CFO Danilo D'Alessandro reported transactions on March 12, 2026.
• 32,627 restricted stock units (RSUs) vested and converted into common stock.
• 16,601 shares were sold at $11.53 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, D'Alessandro directly owns 102,684 shares of common stock.
• D'Alessandro also directly owns 32,626 derivative securities.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine insider transaction related to executive compensation, with the sale of shares for tax purposes being a common occurrence.

Positives

• Vesting of 32,627 restricted stock units indicates continued executive compensation and alignment with shareholder interests.

Negatives

• Sale of 16,601 shares, even for tax purposes, reduces the CFO's direct common stock ownership.

Future Outlook

This filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that RSU vesting and subsequent tax-related sales are routine events for executives, reflecting standard compensation practices in the medical device or neuro-technology industry.

Stakeholder Impact

• Shareholders: Minor dilution from RSU vesting, but the overall impact is negligible given the routine nature of the transaction.

Key Dates

Recommendation

This Form 4 details a routine vesting of restricted stock units and a subsequent sale of shares to cover tax obligations by the CFO. Such transactions are common and do not typically signal a change in the company's fundamentals or management's long-term outlook, thus a 'hold' recommendation is maintained based solely on this filing.

Keywords

ClearPoint Neuro, CLPT, Form 4, insider transaction, RSU vesting, stock sale, CFO, beneficial ownership, tax withholding